Literature DB >> 15838412

The relationship of membership in research networks to compliance with treatment guidelines for early-stage breast cancer.

Linda Laliberte1, Mary L Fennell, George Papandonatos.   

Abstract

BACKGROUND: Research has shown that older women with breast cancer are less likely than younger women to receive treatment in accordance with accepted guidelines. Cancer-related research networks (eg, Comprehensive Cancer Centers) have been funded by the National Cancer Institute to increase the dissemination of new treatment strategies, but little is known about their relationship to cancer treatment patterns.
OBJECTIVES: We used a 3-level hierarchical regression model to examine the relationship of treating facilities' memberships in cancer research networks to compliance with guidelines for primary treatment of early stage breast cancer, controlling for patient and facility factors. RESEARCH
DESIGN: We analyzed data from a database linking SEER registry data and Medicare claims in patients aged 65 years of age or older with early-stage breast cancer to data on the treating facility, including variables that indicate membership(s) in cancer research networks.
SUBJECTS: A total of 16,600 women with stage I or stage II breast cancer, diagnosed between 1990 and 1994, and who received treatment in one of 423 facilities were studied. MEASURES: The key independent variable in this analysis was membership in NCI-funded cancer research networks. The outcome measure is a 3-category variable defined as (1) mastectomy (MAST), (2) breast-conserving surgery plus radiation therapy (BCS+RT), or (3) BCS alone.
RESULTS: Patients treated at facilities that were members of 2 or more cancer research networks were more likely to receive guideline-concordant treatment (ie, MAST or BCS+RT) than similar patients treated at non-member facilities.
CONCLUSIONS: Organizational factors may influence compliance with treatment guidelines and be useful in improving the quality of care.

Entities:  

Mesh:

Year:  2005        PMID: 15838412     DOI: 10.1097/01.mlr.0000160416.66188.f5

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  29 in total

1.  The adoption of alcohol pharmacotherapies in the Clinical Trials Network: the influence of research network participation.

Authors:  Amanda J Abraham; Hannah K Knudsen; Tanja C Rothrauff; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2010-02-01

2.  Innovation adoption in substance abuse treatment: exposure, trialability, and the Clinical Trials Network.

Authors:  Lori J Ducharme; Hannah K Knudsen; Paul M Roman; J Aaron Johnson
Journal:  J Subst Abuse Treat       Date:  2007-02-22

3.  Sustainability and performance of the National Cancer Institute's Community Clinical Oncology Program.

Authors:  William R Carpenter; Alice K Fortune-Greeley; Leah L Zullig; Shoou-Yih Lee; Bryan J Weiner
Journal:  Contemp Clin Trials       Date:  2011-10-02       Impact factor: 2.226

4.  The role of organizational affiliations and research networks in the diffusion of breast cancer treatment innovation.

Authors:  William R Carpenter; Katherine Reeder-Hayes; John Bainbridge; Anne-Marie Meyer; Keith D Amos; Bryan J Weiner; Paul A Godley
Journal:  Med Care       Date:  2011-02       Impact factor: 2.983

5.  Translating research into practice: the role of provider-based research networks in the diffusion of an evidence-based colon cancer treatment innovation.

Authors:  William R Carpenter; Anne-Marie Meyer; Yang Wu; Bahjat Qaqish; Hanna K Sanoff; Richard M Goldberg; Bryan J Weiner
Journal:  Med Care       Date:  2012-08       Impact factor: 2.983

6.  Race and age disparities in receipt of sentinel lymph node biopsy for early-stage breast cancer.

Authors:  Katherine E Reeder-Hayes; John Bainbridge; Anne Marie Meyer; Keith D Amos; Bryan J Weiner; Paul A Godley; William R Carpenter
Journal:  Breast Cancer Res Treat       Date:  2011-02-22       Impact factor: 4.872

7.  Geographic variation and physician specialization in the use of percutaneous biopsy for breast cancer diagnosis.

Authors:  Claire M B Holloway; Refik Saskin; Lawrence Paszat
Journal:  Can J Surg       Date:  2008-12       Impact factor: 2.089

8.  Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network.

Authors:  Hannah K Knudsen; Amanda J Abraham; J Aaron Johnson; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2009-07-03

9.  Influence of NCI cancer center attendance on mortality in lung, breast, colorectal, and prostate cancer patients.

Authors:  Tracy Onega; Eric J Duell; Xun Shi; Eugene Demidenko; Daniel Gottlieb; David C Goodman
Journal:  Med Care Res Rev       Date:  2009-05-19       Impact factor: 3.929

10.  Improving clinical research and cancer care delivery in community settings: evaluating the NCI community cancer centers program.

Authors:  Steven B Clauser; Maureen R Johnson; Donna M O'Brien; Joy M Beveridge; Mary L Fennell; Arnold D Kaluzny
Journal:  Implement Sci       Date:  2009-09-26       Impact factor: 7.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.